Barcoded bulk QTL mapping reveals highly polygenic and epistatic architecture of complex traits in yeast.
Nguyen Ba AN, Lawrence KR, Rego-Costa A, Gopalakrishnan S, Temko D, Michor F, Desai MM.
Elife. 2022 Feb 11. 11. PMID: 35147078
Primary Faculty
Franziska Michor
Other Positions
Professor of Stem Cell and Regenerative Biology
Stem Cell and Regenerative Biology -Sr. Faculty
Harvard Faculty of Arts and Sciences
Professor of Stem Cell and Regenerative Biology
Stem Cell and Regenerative Biology
Harvard Medical School
Links
Overview
Dr. Michor is a Professor of Computational Biology in the Department of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute, in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, and in the Department of Stem Cells and Regenerative Biology at Harvard University. Dr. Michor obtained her undergraduate training in mathematics and molecular biology from the University of Vienna, Austria, and her PhD from the Department of Organismic and Evolutionary Biology at Harvard University. Afterwards, she was awarded a fellowship from the Harvard Society of Fellows. From 2007 until 2010, she was an Assistant Professor in the Computational Biology Program at Memorial Sloan-Kettering Cancer Center. Dr. Michor is the director of the Dana-Farber Cancer Institute Physical Sciences-Oncology Center and the Center for Cancer Evolution. She has been the recipient of the Theodosius Dobzhansky Prize of the Society for the Study of Evolution, the Alice Hamilton Award , the Vilcek Prize for Creative Promise in Biomedical Science, the 36th Annual AACR Award for Outstanding Achievement in Cancer Research, and others. Dr. Michor's laboratory investigates the evolutionary dynamics of cancer initiation, progression, response to therapy, and emergence of resistance.
Bibliography
Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms.
Van Egeren D, Kamaz B, Liu S, Nguyen M, Reilly CR, Kalyva M, DeAngelo DJ, Galinsky I, Wadleigh M, Winer ES, Luskin MR, Stone RM, Garcia JS, Hobbs GS, Michor F, Cortes-Ciriano I, Mullally A, Hormoz S.
Exp Hematol. 2022 03. 107:14-19. PMID: 34921959
Response to comment on "Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2".
Nicholson MD, Endler L, Popa A, Genger JW, Bock C, Michor F, Bergthaler A.
Sci Transl Med. 2021 Oct 27. 13(617):eabj3222. PMID: 34705522
Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses.
Koh SB, Dontchos BN, Bossuyt V, Edmonds C, Cristea S, Melkonjan N, Mortensen L, Ma A, Beyerlin K, Denault E, Niehoff E, Hirz T, Sykes DB, Michor F, Specht M, Lehman C, Ellisen LW, Spring LM.
NPJ Precis Oncol. 2021 Sep 21. 5(1):85. PMID: 34548623
Dissecting dual roles of MyoD during lineage conversion to mature myocytes and myogenic stem cells.
Yagi M, Ji F, Charlton J, Cristea S, Messemer K, Horwitz N, Di Stefano B, Tsopoulidis N, Hoetker MS, Huebner AJ, Bar-Nur O, Almada AE, Yamamoto M, Patelunas A, Goldhamer DJ, Wagers AJ, Michor F, Meissner A, Sadreyev RI, Hochedlinger K.
Genes Dev. 2021 09 01. 35(17-18):1209-1228. PMID: 34413137
Topological isolation of developmental regulators in mammalian genomes.
Wu HJ, Landshammer A, Stamenova EK, Bolondi A, Kretzmer H, Meissner A, Michor F.
Nat Commun. 2021 08 12. 12(1):4897. PMID: 34385432
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F.
Nat Commun. 2021 06 17. 12(1):3697. PMID: 34140482
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
Janiszewska M, Stein S, Metzger Filho O, Eng J, Kingston NL, Harper NW, Rye IH, Aleckovic M, Trinh A, Murphy KC, Marangoni E, Cristea S, Oakes B, Winer EP, Krop IE, Russnes HG, Spellman PT, Bucher E, Hu Z, Chin K, Gray JW, Michor F, Polyak K.
JCI Insight. 2021 06 08. 6(11). PMID: 33886505
Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia.
Zee BM, Poels KE, Yao CH, Kawabata KC, Wu G, Duy C, Jacobus WD, Senior E, Endress JE, Jambhekar A, Lovitch SB, Ma J, Dhall A, Harris IS, Blanco MA, Sykes DB, Licht JD, Weinstock DM, Melnick A, Haigis MC, Michor F, Shi Y.
iScience. 2021 Jun 25. 24(6):102651. PMID: 34151238
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.
Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE.
Cancer Discov. 2021 10. 11(10):2474-2487. PMID: 33941592
News
Franziska Michor wins 2015 Vilcek Prize for Creative Promise
Franziska Michor, associate professor of computational biology, has won a 2015 Vilcek Prize for Creative Promise in Biomedical Science. Michor was chosen for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of…
Franziska Michor honored at second annual Alice Hamilton lecture
May 11, 2012 Franziska Michor, associate professor of computational biology, received Harvard School of Public Health’s second annual Alice Hamilton Award on April 11, 2012 in recognition of her pathbreaking work applying evolutionary theory to cancer. The award,…
